Proving SGLT2 Inhibitor-Mediated Improvement in Cardiomyocyte Energetics: Beyond a Reasonable Doubt?
Circulation: Heart Failure · 2024
DOI: 10.1161/circheartfailure.124.011646 ↗Kurz gefasst
Editorial in der Zeitschrift Circulation: Heart Failure, 2024. Verfasst von Mallory Filipp und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology (M.F.), Northwestern University Feinberg School of Medicine, Chicago, IL. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Myocytes, Cardiac, Energy Metabolism. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS.
Abstract (Originalsprache)
Cardiometabolic heart failure (HF) with preserved ejection fraction (HFpEF) is associated with systemic metabolic disease, including obesity, diabetes, dyslipidemia, and hypertension.Despite its high morbidity and mortality, the list of effective therapeutics for HFpEF remains short.Sodium glucose cotransporter 2 (SGLT2) inhibitors have gained US Food and Drug Administration approval for targeting hyperglycemia by inhibiting renal reabsorption of glucose and sodium.Recent clinical trials have revealed the benefit of empagliflozin and dapagliflozin in reducing HF hospitalizations in patients with HFpEF even in the absence of diabetes, leading to the approval of SGLT2 inhibitors as a foundational treatment for HF across the ejection fraction spectrum.1,2 The reduction in HF hospitalizations in these trials occurs as early as approximately 2 weeks after randomization, suggesting that the SGLT2 inhibitor-mediated reductions in cardiac filling pressures are paramount to their beneficial effects in HF.SGLT2 inhibitors have also been shown to reduce systemic, cardiac, and adipose tissue inflammation.3,4 However, it remains unclear how SGLT2 inhibition is mechanistically mediating these cardiovascular and inflammatory benefits-especially in the absence of diabetes-as there is no evidence of myocardial or immune expression of SGLT2.5 In this issue of Circulation: Heart Failure, Schauer et al begin to explore how SGLT2 inhibitors may be modulating cardiac metabolism and function in a murine model of HFpEF.6 By 24 weeks of age, obese Zucker fatty and spontaneously hypertensive (ZSF1) rats develop obesity, hyperglycemia, hypertension, and signs of diastolic dysfunction, such as an elevated E/e', with a preserved ejection fraction.Whether treatment with the SGLT2 inhibitor empagliflozin could improve cardiac function was mechanistically explored in this model.Compared to placebo, empagliflozin reduced both E/e' (an echocardiographic estimate of left ventricular [LV] filling pressure) and directly measured LV end-diastolic
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology (M.F.), Northwestern University Feinberg School of Medicine, Chicago, IL.
- Division of Cardiology, Department of Medicine (S.J.S.), Northwestern University Feinberg School of Medicine, Chicago, IL.
ORCID-Profile: Mallory Filipp
Förderung
- NHLBI NIH HHS
Zitieren
APA
Filipp, M., & Shah, S. J. (2024). Proving SGLT2 Inhibitor-Mediated Improvement in Cardiomyocyte Energetics: Beyond a Reasonable Doubt?. Circulation: Heart Failure. https://doi.org/10.1161/circheartfailure.124.011646
Vancouver
Filipp M, Shah SJ. Proving SGLT2 Inhibitor-Mediated Improvement in Cardiomyocyte Energetics: Beyond a Reasonable Doubt?. Circulation: Heart Failure. 2024. doi:10.1161/circheartfailure.124.011646
BibTeX
@article{Filipp2024,
author = {Filipp, Mallory and Shah, Sanjiv J},
title = {Proving SGLT2 Inhibitor-Mediated Improvement in Cardiomyocyte Energetics: Beyond a Reasonable Doubt?},
journal = {Circulation: Heart Failure},
year = {2024},
doi = {10.1161/circheartfailure.124.011646}
}
EUVIMED